Back
Day Range
$10.64
$10.99
52-Week Range
$5.30
$14.85
Volume
167,071
50D / 200D Avg
$12.40
/
$9.41
Prev Close
$11.09
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (627 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -12.3 | 0.3 |
| P/B | 1.7 | 2.9 |
| ROE % | -12.0 | 3.7 |
| Net Margin % | -7.9 | 3.8 |
| Rev Growth 5Y % | -0.2 | 10.0 |
| D/E | 1.4 | 0.2 |
Analyst Price Target
No analyst coverage available
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2029 |
$1.45
$1.42 – $1.49
|
50 B | 1 |
| FY2028 |
$1.27
$1.25 – $1.31
|
48 B | 1 |
| FY2027 |
$1.18
$1.10 – $1.26
|
47 B | 2 |
Key Takeaways
Revenue declined -0.17% annually over 5 years
Generating 2.00B in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 5.90%
Capital efficient — spends only 5.46% of revenue on capex
Growth
Revenue Growth (5Y)
-0.17%
Revenue (1Y)-6.07%
Earnings (1Y)N/A
FCF Growth (3Y)-8.02%
Quality
Return on Equity
-12.02%
ROIC7.91%
Net Margin-7.94%
Op. Margin15.26%
Safety
Debt / Equity
1.44
Current Ratio1.00
Interest Coverage4.04
Valuation
P/E Ratio
-12.32
P/B Ratio1.65
EV/EBITDA11.02
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -6.07% | Revenue Growth (3Y) | -4.14% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -0.17% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 43.78B | Net Income (TTM) | -3.48B |
| ROE | -12.02% | ROA | -3.15% |
| Gross Margin | 59.21% | Operating Margin | 15.26% |
| Net Margin | -7.94% | Free Cash Flow (TTM) | 2.00B |
| ROIC | 7.91% | FCF Growth (3Y) | -8.02% |
| Safety | |||
| Debt / Equity | 1.44 | Current Ratio | 1.00 |
| Interest Coverage | 4.04 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | -12.32 | P/B Ratio | 1.65 |
| P/S Ratio | 0.98 | PEG Ratio | -0.29 |
| EV/EBITDA | 11.02 | Dividend Yield | 0.00% |
| Market Cap | 42.83B | Enterprise Value | 73.59B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 43.78B | 46.61B | 47.64B | 50.74B | 44.08B |
| Net Income | -3.48B | -2.55B | -2.94B | 4.15B | 1.00B |
| EPS (Diluted) | -0.88 | -0.65 | -0.75 | 1.06 | 0.26 |
| Gross Profit | 25.92B | 25.34B | 27.89B | 30.87B | 27.27B |
| Operating Income | 6.68B | 3.33B | -150.00M | 6.26B | 6.98B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 110.56B | 110.85B | 116.26B | 124.88B | 120.24B |
| Total Liabilities | 84.51B | 78.81B | 83.18B | 85.95B | 87.07B |
| Shareholders' Equity | 25.94B | 31.91B | 32.93B | 38.77B | 33.02B |
| Total Debt | 37.43B | 40.70B | 44.79B | 41.65B | 39.53B |
| Cash & Equivalents | 6.67B | 6.19B | 5.91B | 5.17B | 4.56B |
| Current Assets | 32.43B | 34.44B | 37.56B | 37.76B | 32.58B |
| Current Liabilities | 32.57B | 28.95B | 29.46B | 35.08B | 29.40B |